Allergy Relief D (fexofenadine HCL and pseudoephedrine HCL) extended-release tablets are being recalled because they failed to meet dissolution testing specifications. This means the tablets may not release the medication properly into the body as intended. The recall affects 25,176 units of the 30-count cartons and 22,968 units of the 20-count cartons, which were sold at Walmart stores nationwide. No injuries or incidents have been reported in connection with this issue.
The tablets may not dissolve correctly, which can result in the medication being less effective or failing to work as expected. This could lead to a lack of relief from allergy symptoms or nasal congestion.
You have 2 options:
Distributed by Walmart Inc.
Distributed by Walmart Inc.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.